Cipla
INTRODUCTION:
Cipla Limited is an Indian pharmaceutical company, Founded by nationalist Indian scientist Khwaja
Abdul
Hamied as The
Chemical,
Industrial
&
Pharmaceutical
Laboratories .Cipla laid foundations for the Indian pharmaceutical industry way back in 1935 with the vision to make India self-reliant and self-sufficient in healthcare. Legacy of innovation and an entrepreneurial spirit ingrained by the founder, Dr. K.A Hamied and propounded by the present Chairman and Managing Director, Dr. Yusuf Khwaja Hamied .Over the past 77 years,
Cipla has emerged as one of the most respected pharmaceutical names not just in India but worldwide. The company‟s headquarter is in Mumbai, India. Cipla produces one of the widest range of products and dosage forms in the world today, everything from metered-dose inhalers, pre-filled syringes, trans-dermal spray patches, lyophilized injections, nasal sprays, medical devices, and thermo labile foams. The company Revenue is around 6977million and turnover is around 1 billion. Cipla‟s Business model is based on international strategic alliances and focus on pursuing organic growth while reducing capital commitment and regulatory/litigation risks.
Cipla makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions, and its products are distributed in virtually every country of the world. And probably best-known outside its home country for pioneering the manufacture of low-cost anti-AIDS drugs for HIV-positive patients in developing countries. It has played a similarly prominent role in expanding access to drugs to fight influenza, respiratory disease and cancer.
Cipla has over 34 state-of-the-art manufacturing units which have been approved by various
Ministries of Health and Regulatory Authorities like US FDA, WHO, MCC -South Africa, MHRAUK, TGA-Australia among others. In addition, Cipla‟s manufacturing facilities are GCMP compliant in
Cipla Limited is an Indian pharmaceutical company, Founded by nationalist Indian scientist Khwaja
Abdul
Hamied as The
Chemical,
Industrial
&
Pharmaceutical
Laboratories .Cipla laid foundations for the Indian pharmaceutical industry way back in 1935 with the vision to make India self-reliant and self-sufficient in healthcare. Legacy of innovation and an entrepreneurial spirit ingrained by the founder, Dr. K.A Hamied and propounded by the present Chairman and Managing Director, Dr. Yusuf Khwaja Hamied .Over the past 77 years,
Cipla has emerged as one of the most respected pharmaceutical names not just in India but worldwide. The company‟s headquarter is in Mumbai, India. Cipla produces one of the widest range of products and dosage forms in the world today, everything from metered-dose inhalers, pre-filled syringes, trans-dermal spray patches, lyophilized injections, nasal sprays, medical devices, and thermo labile foams. The company Revenue is around 6977million and turnover is around 1 billion. Cipla‟s Business model is based on international strategic alliances and focus on pursuing organic growth while reducing capital commitment and regulatory/litigation risks.
Cipla makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions, and its products are distributed in virtually every country of the world. And probably best-known outside its home country for pioneering the manufacture of low-cost anti-AIDS drugs for HIV-positive patients in developing countries. It has played a similarly prominent role in expanding access to drugs to fight influenza, respiratory disease and cancer.
Cipla has over 34 state-of-the-art manufacturing units which have been approved by various
Ministries of Health and Regulatory Authorities like US FDA, WHO, MCC -South Africa, MHRAUK, TGA-Australia among others. In addition, Cipla‟s manufacturing facilities are GCMP compliant in